UY33317A - Nuevos derivados de pirazol - Google Patents
Nuevos derivados de pirazolInfo
- Publication number
- UY33317A UY33317A UY0001033317A UY33317A UY33317A UY 33317 A UY33317 A UY 33317A UY 0001033317 A UY0001033317 A UY 0001033317A UY 33317 A UY33317 A UY 33317A UY 33317 A UY33317 A UY 33317A
- Authority
- UY
- Uruguay
- Prior art keywords
- pirazol
- new derivatives
- sphingosine
- agonists
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a un compuesto de fórmula (I), al procedimiento para preparar dichos compuestos y a su uso en el tratamiento de una condición patológica o enfermedad susceptible de mejorar por agonistas de los receptores de 1-fosfato de esfingosina (S1P1).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10382128A EP2390252A1 (en) | 2010-05-19 | 2010-05-19 | New pyrazole derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
UY33317A true UY33317A (es) | 2011-10-31 |
Family
ID=42664897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001033317A UY33317A (es) | 2010-05-19 | 2011-04-06 | Nuevos derivados de pirazol |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2390252A1 (es) |
TW (1) | TW201141858A (es) |
UY (1) | UY33317A (es) |
WO (1) | WO2011144338A1 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3184526T (pt) | 2005-12-13 | 2018-12-19 | Incyte Holdings Corp | Derivados de pirrolo[2,3-d]pirimidina como inibidores da cinase janus |
US20080312259A1 (en) | 2007-06-13 | 2008-12-18 | Incyte Corporation | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE |
CN106967070A (zh) | 2009-05-22 | 2017-07-21 | 因塞特控股公司 | 作为jak抑制剂的化合物 |
ES2487542T3 (es) | 2009-05-22 | 2014-08-21 | Incyte Corporation | Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus |
AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
TWI766281B (zh) | 2010-03-10 | 2022-06-01 | 美商英塞特控股公司 | 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物 |
PE20130216A1 (es) | 2010-05-21 | 2013-02-27 | Incyte Corp | Formulacion topica para un inhibidor de jak |
JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
AR083933A1 (es) | 2010-11-19 | 2013-04-10 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
EA201490042A1 (ru) | 2011-06-20 | 2014-10-30 | Инсайт Корпорейшн | Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
SG11201503695XA (en) | 2012-11-15 | 2015-06-29 | Incyte Corp | Sustained-release dosage forms of ruxolitinib |
US20140235587A1 (en) * | 2013-02-15 | 2014-08-21 | Allergan, Inc. | Substituted pyrazoles as sphingosine receptor modulators |
US20140235588A1 (en) * | 2013-02-15 | 2014-08-21 | Allergan, Inc. | Substituted 1h-pyrazol-1,2,4-oxadiazole derivatives as sphingosine receptor modulators |
PL2958913T3 (pl) * | 2013-02-20 | 2019-03-29 | Lg Chem, Ltd. | Agoniści receptora sfingozyno-1-fosforanowego, sposoby ich przygotowania i zawierające je jako środek aktywny farmaceutyczne kompozycje |
HUE057262T2 (hu) | 2013-03-06 | 2022-04-28 | Incyte Holdings Corp | Eljárás és köztitermékek JAK inhibitor elõállítására |
US9655854B2 (en) | 2013-08-07 | 2017-05-23 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
CN105899504A (zh) * | 2014-01-21 | 2016-08-24 | 豪夫迈·罗氏有限公司 | 用于治疗和预防呼吸道合胞病毒感染的咪唑化合物 |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
KR20180036415A (ko) | 2016-09-30 | 2018-04-09 | 재단법인 한국파스퇴르연구소 | 신규 헤테로아릴 화합물, 이의 거울상 이성질체, 부분 입체 이성질체 또는 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 항바이러스용 조성물 |
AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
CN112105608B (zh) | 2018-01-30 | 2023-07-14 | 因赛特公司 | 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法 |
AU2019245420A1 (en) | 2018-03-30 | 2020-11-12 | Incyte Corporation | Treatment of hidradenitis suppurativa using JAK inhibitors |
AR117169A1 (es) | 2018-11-28 | 2021-07-14 | Bayer Ag | (tio)amidas de piridazina como compuestos fungicidas |
US20230348392A1 (en) | 2020-05-06 | 2023-11-02 | Bayer Aktiengesellschaft | Pyridine (thio)amides as fungicidal compounds |
JP2023525349A (ja) | 2020-05-12 | 2023-06-15 | バイエル、アクチエンゲゼルシャフト | 殺真菌性化合物としてのトリアジンおよびピリミジン(チオ)アミド化合物 |
CN115803317A (zh) | 2020-05-19 | 2023-03-14 | 拜耳作物科学股份公司 | 作为杀真菌化合物的氮杂双环(硫代)酰胺 |
US20230165252A1 (en) | 2020-05-27 | 2023-06-01 | Bayer Aktiengesellschaft | Active compound combinations |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2022065940A1 (ko) * | 2020-09-28 | 2022-03-31 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제의 용도 |
TW202222314A (zh) * | 2020-09-28 | 2022-06-16 | 南韓商Lg化學股份有限公司 | 神經鞘胺醇-1-磷酸受體促效劑的用途 |
WO2022080812A1 (ko) * | 2020-10-13 | 2022-04-21 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조 방법 |
WO2022220593A1 (ko) * | 2021-04-14 | 2022-10-20 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제를 포함하는 직접 타정용 약제학적 조성물 |
WO2022220596A1 (ko) * | 2021-04-14 | 2022-10-20 | 주식회사 엘지화학 | 습식과립법에 의한 스핑고신-1-인산 수용체 효능제를 포함하는 경구용 고형 제제의 제조 방법 |
US20240207242A1 (en) * | 2021-04-14 | 2024-06-27 | Lg Chem, Ltd. | Pharmaceutical composition comprising sphingosine-1-phosphate receptor agonist with controlled particle size |
WO2022220595A1 (ko) * | 2021-04-14 | 2022-10-20 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제를 포함하는 고형 제제의 제조 방법 |
WO2023078915A1 (en) | 2021-11-03 | 2023-05-11 | Bayer Aktiengesellschaft | Bis(hetero)aryl thioether (thio)amides as fungicidal compounds |
WO2024068950A1 (en) | 2022-09-30 | 2024-04-04 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
WO2024068947A1 (en) | 2022-09-30 | 2024-04-04 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994000943A1 (en) | 1992-06-23 | 1994-01-06 | Motorola, Inc. | Multi-modulation scheme compatible radio |
CZ294782B6 (cs) | 1995-06-21 | 2005-03-16 | Sofotec Gmbh & Co. Kg | Inhalátor pro prášková léčiva |
DE10129703A1 (de) | 2001-06-22 | 2003-01-02 | Sofotec Gmbh & Co Kg | Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren |
DE10202940A1 (de) | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
CA2483594C (en) | 2002-05-16 | 2011-02-15 | Novartis Ag | Use of edg receptor binding agents in cancer |
GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
EP1484057A1 (en) | 2003-06-06 | 2004-12-08 | Aventis Pharma Deutschland GmbH | Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain |
AU2004271804B2 (en) | 2003-09-12 | 2011-01-06 | Newron Sweden Ab | Treatment of disorders of the nervous system |
GB0329498D0 (en) | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
EP1616592B9 (en) | 2004-07-16 | 2011-02-02 | Almirall, S.A. | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge for use with this inhaler |
BRPI0707281A2 (pt) | 2006-01-27 | 2011-04-26 | Univ Virginia | método para prevenção ou tratamento de dor neuropática em um mamìfero |
TWI389683B (zh) | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
US8318812B2 (en) | 2006-06-02 | 2012-11-27 | The Ohio State University Research Foundation | Therapeutic agents for the treatment of lymphoid malignancies |
GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
CN101553216B (zh) | 2006-08-17 | 2012-03-21 | 芝加哥大学 | 炎性疾病的治疗 |
NZ577111A (en) * | 2006-12-15 | 2012-05-25 | Abbott Lab | Novel oxadiazole compounds |
WO2008141731A2 (en) * | 2007-05-18 | 2008-11-27 | Bayer Healthcare Ag | Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
PT2291080E (pt) * | 2008-05-14 | 2015-10-30 | Scripps Research Inst | Novos modelamodeladores dos recetores da esfingosina fosfato |
-
2010
- 2010-05-19 EP EP10382128A patent/EP2390252A1/en not_active Withdrawn
-
2011
- 2011-04-06 UY UY0001033317A patent/UY33317A/es not_active Application Discontinuation
- 2011-04-19 TW TW100113565A patent/TW201141858A/zh unknown
- 2011-05-18 WO PCT/EP2011/002487 patent/WO2011144338A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
TW201141858A (en) | 2011-12-01 |
WO2011144338A1 (en) | 2011-11-24 |
EP2390252A1 (en) | 2011-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY33317A (es) | Nuevos derivados de pirazol | |
UY32296A (es) | Nuevos compuestos | |
CL2016001732A1 (es) | Métodos sintéticos para compuestos espiro-oxoindol (div. sol. 3633-13). | |
GT201400136A (es) | Compuestos y métodos de benzaldehído substituído para su uso en incrementar la oxigenación de los tejidos | |
CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
CU20110052A7 (es) | Compuestos orgánicos | |
UY32292A (es) | Agonistas de s1p1 y métodos de preparación y uso | |
BR112014003597A2 (pt) | composto da fórmula i, processo de preparação de compostos da fórmula i, composto da fórmula xii, composto das fórmulas viii e xi, composição agroquímica, uso de compostos da fórmula i ou viii e semente revestida com pelo menos um composto da fórmula i ou viii | |
CR20120264A (es) | Compuestos | |
ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
UY33587A (es) | Nuevos compuestos como inhibidores de quinasas syk y jak | |
BR112014002922A2 (pt) | compostos da fórmula i, processo de preparação de compostos da fórmula i, compostos da formula xii, viii e xi, composições agroquímicas, uso e semente | |
ECSP13012611A (es) | Derivados de pirazol-aminopirimidina como moduladores de la lrrk2 | |
UY35683A (es) | Polimorfo de inhibidores de tirosina quinasa de bazo (syk) | |
CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
DOP2009000237A (es) | Derivados de indazol oxadiazol sustituidos para uso como agonistas esfingosina 1-fosfato (s1p) | |
DOP2012000263A (es) | Compuestos quimicos | |
ECSP13012596A (es) | Proceso de elaboración para derivados de pirimidina | |
BR112015004029A2 (pt) | Processo para preparação de teneligliptina, de um composto ou de sal ou hidrato do mesmo | |
CR20150245A (es) | Proceso novedoso para la elaboración de compuestos para uso en el tratamiento de cáncer | |
CL2012002082A1 (es) | Proceso para la preparacion de lacosamida, por hidroximetilación; compuestos intermediarios. | |
BR112014031091A2 (pt) | Derivados de piperidina para agonista de gpr119 | |
BR112014001539A2 (pt) | processo para obter uma composição contendo fatores de crescimento de um composto do sangue, e composição obtida pelo dito processo | |
CR20160016A (es) | Pirazolpiridinas sustituidas | |
CR20120592A (es) | Intermedios de agomelatina y métodos de preparación de estos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
104 | Application deemed to be withdrawn (no substantive examination fee paid) |
Effective date: 20130802 |